CRTX Financial Facts
Interest expense, net: -1.68MNet income (loss) per share, diluted: 0.31
See Full Income Statement
Accounts receivable, net: 29.8M
Total current assets: 126.09M
See Full Balance Sheet
Cornerstone Therapeutics Inc. (CRTX) Earnings
|
Expand Research on CRTX
Next EPS Date | N/A | EPS Growth Rate | N/A |
---|---|---|---|
Average EPS % Beat Rate | -68.0% | Revenue Growth Rate | N/A |
Average % Move 1-Wk after EPS | +5.9% | Normal Earnings Time | Before Open |
Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
---|---|---|---|---|---|---|---|---|---|---|---|
3/8/12 | Q411 | -$0.06 | $0.09 | -$0.15 | $18.21M | $24.58M | N/A | Details | |||
8/6/13 | Q213 | $0.19 | $0.12 | +$0.07 | $40.4M | $35.79M | N/A | Details | |||
8/9/12 | Q212 | -$0.17 | -$0.02 | -$0.15 | $21.47M | $18.84M | N/A | Details | |||
11/8/12 | Q312 | $0.19 | $0.32 | -$0.13 | $37.5M | $32M | N/A | Details | |||
3/14/13 | Q412 | -$0.26 | $0.10 | -$0.36 | $34.93M | $36.04M | N/A | Details | |||
5/12/11 | Q111 | $0.17 | $0.15 | +$0.02 | $29.98M | $29.63M | N/A | Details | |||
11/7/13 | Q313 | $0.46 | $0.27 | +$0.19 | $53.7M | $42M | N/A | Details | |||
11/4/10 | Q310 | $0.15 | $0.04 | +$0.11 | N/A | N/A | N/A | Details |